sellaslifesciences.com (SLS): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
SELLAS Life Sciences (SLS) maintains a stable market position driven by peptide patents and the final stages of leukemia immunotherapy development. This chart reflects an asset valuation of 0.00, which exists alongside threats of underfunding and potential clinical trial failures. The business's financial success relies on the future commercialization of anti-tumor vaccines designed to curb patient relapses.
SLS (sellaslifesciences.com): analytical breakdowns and indicator data
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital SELLAS Life Sciences|SLS - Long-Term Liabilities to Capital|Short-Term Debt to Equity SELLAS Life Sciences Group|SLS - Company Debts|Debt to Book Capitalization Ratio SELLAS Life Sciences|SLS - Company Long-Term Debt|Company Short-Term Debts SELLAS Life Sciences|Quick Liquidity sellaslifesciences.com
- financial results and valuation multiples details:
SLS - Net Financial Result|Future Profit SELLAS Life Sciences|SLS - Company Value to Net Income|Future Price to Earnings SELLAS Life Sciences Group|SLS - Price/Earnings to Growth Ratio|EV/EBITDA Multiple SELLAS Life Sciences|SLS - Operating income before deduction of amortization|Net earnings per share (EPS TTM) SELLAS Life Sciences|SLS - Earnings per one share for the last 12 months|Quarterly EPS earnings growth sellaslifesciences.com|SLS - Earnings per share growth rate in current year|Expected earnings per share growth for next year SELLAS Life Sciences
Summary company analytics:SLS (SELLAS Life Sciences Group Inc.)
When constructing a long-term portfolio, the primary screening filter is the valuation of the business relative to its operating profit. This ratio compares enterprise value (EV) to EBITDA, determining the payback period of the assets. For SELLAS Life Sciences (SLS), such a metric is critical, as the capital-intensive development of targeted vaccines requires large-scale financing. By analyzing the historical EV/EBITDA levels of SELLAS Life Sciences (SLS), an investor can assess the business's resilience to its debt load.
Who SELLAS Life Sciences competes with
BeiGene Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Halozyme Corp HALO|RVMD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation AAPG (ascentage.com)|CGON: EV/EBITDA Multiple|Company Value to EBITDA UroGen Pharma Ltd (URGN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bicara Bio|Personalis Genomics (PSNL) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ERAS|DCTH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Therapeutics, Inc. YMAB|Aura Biosciences Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ARAY: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU: EV/EBITDA Multiple|citiusonc.com (CTOR) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TuHURA Biosciences Inc.|Protara Therapeutics Inc (TARA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|WHWK (aadibio.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TScan Therapeutics, Inc. TCRX|Champions Oncology Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBiotech USA - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio CEL-SCI Corporation CVM|OSTX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio RADX (Radiopharm Theranostics Ltd)|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Adlai Nortye Limited ANL|Enterprise Value to EBITDA Ratio VERU (Veru)|TPST (Tempest Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|Total Company Value to Operating Income Before Depreciation Ratio Renovaro Biosciences (RENB)|Mural Bio - EV/EBITDA Multiple|Kairos Pharma Ltd (KAPA) - Enterprise Value to EBITDA Ratio|OKUR: EV/EBITDA Multiple|GDTC - Total Company Value to Operating Income Before Depreciation Ratio|CRIS (Curis Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Apollomics Corp APLM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tharimmune, Inc. (THAR)|advanbiomed.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex)|CLDI - Enterprise Value to EBITDA Ratio|Sunshine Biopharma - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PPBT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|BeiGene Ltd. (BGNE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics, Inc (CKPT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ELEV (Elevation Oncology Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|Total Company Value to Operating Income Before Depreciation Ratio Ikena Oncology Inc. (IKNA)|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR: EV/EBITDA Multiple|NAYA Biosciences Corp (NAYA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
